Needham Reiterates Buy on Conmed, Maintains $97 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has reiterated a Buy rating on Conmed (NYSE:CNMD) and maintained a price target of $97.
October 04, 2024 | 5:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Mike Matson has reiterated a Buy rating on Conmed, maintaining a price target of $97. This suggests confidence in Conmed's future performance and potential for stock price appreciation.
The reiteration of a Buy rating and maintenance of a $97 price target by Needham indicates a positive outlook on Conmed's stock. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100